Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.8K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.8K
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing a multi-modal neuroimaging-based BrainAge model across childhood.

bioRxiv : the preprint server for biology·2026
Same author

Positive and negative maternal mental health demonstrate distinct pathways to childhood depression.

Psychological medicine·2026
Same author

Breastfeeding duration and bone mineral density in childhood: a prospective study within the Growing Up in Singapore Toward healthy Outcomes (GUSTO) cohort.

The American journal of clinical nutrition·2026
Same author

A longitudinal study of chronotype stability from preschool-to school-age and its association with sleep problems.

Sleep medicine·2026
Same author

Maternal-prenatal gut microbiome-systemic metabolome perturbations and T<sub>H</sub>2-skewed immunity link to offspring gut microbiome disruption and atopic dermatitis susceptibility.

Genome medicine·2026
Same author

Associations Among Physical Activity, Leukocyte Telomere Length, and Depression in Pregnancy: A Cohort Study.

Women's health issues : official publication of the Jacobs Institute of Women's Health·2026

Related Experiment Video

Updated: May 3, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

8.4K

Progestational agents for treating threatened or established preterm labour.

Lin-Lin Su1, Miny Samuel, Yap-Seng Chong

  • 1Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Hospital, 5 Lower Kent Ridge Wing, Singapore, Singapore, 119074.

The Cochrane Database of Systematic Reviews
|February 1, 2014
PubMed
Summary

Progestational agents show some promise in reducing preterm birth and increasing birthweight, but evidence is limited. More research is needed to confirm their effectiveness as a treatment for preterm labor.

More Related Videos

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

20.0K
Mouse In Vivo Placental Targeted CRISPR Manipulation
07:39

Mouse In Vivo Placental Targeted CRISPR Manipulation

Published on: April 14, 2023

3.7K

Related Experiment Videos

Last Updated: May 3, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

8.4K
Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

20.0K
Mouse In Vivo Placental Targeted CRISPR Manipulation
07:39

Mouse In Vivo Placental Targeted CRISPR Manipulation

Published on: April 14, 2023

3.7K

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Pharmacology

Background:

  • Preterm birth is a leading cause of perinatal morbidity and mortality, often leading to long-term impairment.
  • Existing tocolytic agents have shown mixed results in improving pregnancy duration and neonatal outcomes.
  • Progesterone plays a crucial role in maintaining pregnancy by inhibiting uterine contractility.

Purpose of the Study:

  • To evaluate the efficacy of progestational agents as a treatment or co-treatment for threatened or established preterm labor with intact membranes.

Main Methods:

  • A systematic review of randomized controlled trials was conducted.
  • Searches included Cochrane Pregnancy and Childbirth Group's Trials Register, CENTRAL, MEDLINE, and Embase up to August 2013.
  • Data were independently extracted and trial quality assessed by two reviewers.

Main Results:

  • Seven studies involving 538 women contributed data.
  • Some evidence suggests progestational agents may reduce preterm deliveries before 37 weeks and increase birthweight.
  • Potential benefits include reduced uterine contractions, prolonged pregnancy, and attenuated cervical shortening, though analyses were limited by study numbers and progesterone variations.

Conclusions:

  • Insufficient evidence currently supports the use of progestational agents as a standard tocolytic treatment for preterm labor.
  • Further high-quality research is necessary to establish their role in managing preterm birth.